reports
Team, Inc. Announces Refinancing Transaction
Team, Inc. Announces Refinancing Transaction Lowers Cost of Capital and Terms Out Maturities SUGAR LAND, Texas, March 13, 2025 (GLOBE NEWSWIRE) -- Team, Inc. (NYSE: TISI) (“TEAM” or the “Company”), a global, leading provider of specialty industrial services offering clients access to a full suite of conventional, specialized, and proprietary mechanical, heat-treating, and inspection services, today announced that it has successfully closed on a refinancing transaction (the “Transaction”) that lowers the Company’s cost of capital and terms out its capital structure. The Transaction co...
Clene Demonstrates Strengthened ALS Survival Benefit with CNM-Au8® Tre...
Clene Demonstrates Strengthened ALS Survival Benefit with CNM-Au8® Treatment New Cross-Regimen Analysis of HEALEY ALS Platform Trial Shows Significant Survival Advantage SALT LAKE CITY, March 12, 2025 (GLOBE NEWSWIRE) -- Clene, Inc. (Nasdaq: CLNN) and its subsidiary, Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced new evidence from a cross-regimen, post hoc analysis of long-term survival in HEALEY ALS Plat...
PLAYSTUDIOS, Inc. Announces Fourth Quarter Results
LAS VEGAS--(BUSINESS WIRE)-- PLAYSTUDIOS, Inc. (Nasdaq: MYPS) (“PLAYSTUDIOS” or the “Company”), the creator of the playAWARDS loyalty platform and an award-winning developer and publisher of free-to-play mobile and social games, today announced financial results for the fourth quarter ended December 31, 2024. Andrew Pascal, Chairman and Chief Executive Officer of PLAYSTUDIOS, commented, “2024 closed with revenue and Consolidated AEBITDA in line with guidance despite continued industry pressures. More importantly, we’re entering 2025 with a more structured, cost-efficient business model geared...
- Jonathan Moreland
InsiderInsights Weekly Report: March 8, 2025
InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process
WWW WOLVERINE WORLD WIDE INC.
TTSH TILE SHOP HOLDINGS INC.
TRS TRIMAS CORPORATION
STAA STAAR SURGICAL CO.
SRE SEMPRA ENERGY
SIGI SELECTIVE INSURANCE GROUP INC.
SEDG SOLAREDGE TECHNOLOGIES INC.
PEB PEBBLEBROOK HOTEL TRUST
PBF PBF ENERGY INC. CLASS A
OSUR ORASURE TECHNOLOGIES INC.
MTDR MATADOR RESOURCES COMPANY
LTRX LANTRONIX INC.
JCOM J2 GLOBAL INC.
IFF INTERNATIONAL FLAVORS & FRAGRANCES INC.
FTAI FORTRESS TRANSPORTATION AND INFRASTRUCTURE INVESTORS LLC
FRPT FRESHPET INC
ECPG ENCORE CAPITAL GROUP INC.
CDXS CODEXIS
AMRC AMERESCO
CMCO COLUMBUS MCKINNON CORPORATION
FMC FMC CORPORATION
PETS PETMED EXPRESS INC.
PLBC PLUMAS BANCORP
FLWS 1-800-FLOWERS.COM CL A
JELD JELD-WEN HOLDING INC.
FRAF FRANKLIN FINANCIAL SERVICES CO.
FTDR FRONTDOOR INC.
STRA STRATEGIC EDUCATION INC.
LBSRD LIBERTY STAR URANIUM & METALS
AMCR AMCOR PLC
CCO CLEAR CHANNEL OUTDOOR HOLDINGS INC
PSN PARSONS
PCB PACIFIC CITY FINANCIAL CORP
ENX EATON VANCE NEW YORK MUNICIPAL BOND FUND
ORIC ORIC PHARMACEUTICALS
NOG NORTHERN OIL AND GAS
UAN CVR PARTNERS LP
CLVT CLARIVATE PLC
FLNC FLUENCE ENERGY INC
BHVN BIOHAVEN LTD
ECAT BLACKROCK ESG CAP ALLOCATION TR
MAIA MAIA BIOTECHNOLOGY INC
MBC_w MASTERBRAND INC
MRNA MODERNA
CVI INC.
BHRB CVR ENERGY
GF INC.
BURKE HERBERT FINANCIAL SERVICES CORP
THE NEW GERMANY FUND
INC.
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Ru...
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 07, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on March 3, 2025 (the “Grant Date”), ORIC granted a total of 26,450 non-qualified stock options and 4,300 restricted stock units to three new non-executive employees who began their employment with ORIC in February 2025. These inducement grants were g...
Clene to Present at the 37TH Annual Roth Conference
Clene to Present at the 37TH Annual Roth Conference SALT LAKE CITY, March 06, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will participate in a fireside chat at the 37th Annual Roth Conference and host 1x1 investor meetings. Date: March 18, 2025Time of Presentatio...
- Jonathan Moreland
InsiderInsights.com Daily Ratings Report: March 4, 2025
InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process
VAC MARRIOTT VACATIONS WORLDWIDE CORPORATION
TDOC TELADOC HEALTH INC.
PBF PBF ENERGY INC. CLASS A
OMI OWENS & MINOR INC.
MTDR MATADOR RESOURCES COMPANY
LTRX LANTRONIX INC.
JCOM J2 GLOBAL INC.
FTAI FORTRESS TRANSPORTATION AND INFRASTRUCTURE INVESTORS LLC
FLDM FLUIDIGM
CDXS CODEXIS
FMC FMC CORPORATION
GTN GRAY TELEVISION INC.
PETS PETMED EXPRESS INC.
DMLP DORCHESTER MINERALS L.P.
LBSRD LIBERTY STAR URANIUM & METALS
GO GROCERY OUTLET HOLDING
PSN PARSONS
CAPR CAPRICOR THERAPEUTICS
VERX VERTEX
ORIC INC.
NOG ORIC PHARMACEUTICALS
PFBX NORTHERN OIL AND GAS
ALIT PEOPLES FINANCIAL CORP. (MISSISSIPPI)
TMCI ALIGHT
AVDX INC. / DELAWARE
FLYW TREACE MED CONCEPTS INC
MBC_w AVIDXCHANGE HLDGS INC
MRNA FLYWIRE CORP
CVI MASTERBRAND INC
GF MODERNA
INC.
CVR ENERGY
INC.
THE NEW GERMANY FUND
INC.
- Wedbush Research
ORIC® Pharmaceuticals Announces Focused Registrational Clinical Develo...
ORIC® Pharmaceuticals Announces Focused Registrational Clinical Development Plans for Lead Programs, Extended Cash Runway, and Updated Corporate Milestones Anticipated registrational development plans for ORIC-944 and ORIC-114 prioritized to focus on indications with strongest clinical validation and highest unmet need ORIC-944 initiation of first Phase 3 trial in mCRPC expected in 1H 2026; ORIC-114 registrational development plans to focus on 1L NSCLC with anticipated initiation in 2026 Favorable enrollment across both programs allows for accelerated/augmented corporate milestones,...
- David Nierengarten
- Dennis Pak
- Martin Fan
Clene and APST Enter Into an Agreement to Support FDA’s Recommendation...
Clene and APST Enter Into an Agreement to Support FDA’s Recommendation for Long-Term NfL Biomarker Analyses of CNM-Au8®’s Impact on NfL Reduction Longitudinal ALS patient data from APST Research will enable a more robust analysis of the effect of CNM-Au8 on NfL biomarkersAPST Research data includes thousands of people living with ALS including clinical, survival, and longitudinal NfL data Clene plans to analyze the APST ALS NfL biomarker and clinical dataset to compare NfL change from its ongoing NIH-sponsored EAP to address the FDA’s request for supportive evidence of CNM-Au8’s effect on N...
PLAYSTUDIOS to Release Fourth Quarter and Full Year 2024 Results March...
LAS VEGAS--(BUSINESS WIRE)-- PLAYSTUDIOS, Inc. (Nasdaq: MYPS) (“PLAYSTUDIOS” or the “Company”), the creator of the playAWARDS loyalty platform and an award-winning developer of free-to-play mobile and social games that offer real-world rewards to players, today announced that it will release its fourth quarter and full year 2024 results after the close of the market on Monday, March 10, 2025. The Company will host a conference call and audio webcast on Monday, March 10, 2025 at 5:00 pm Eastern Time to discuss the results. To listen to the audio webcast and live Q&A, please visit the PLAYSTUD...
- Wedbush Research
ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financ...
ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Updates Reported encouraging early safety and efficacy data in ongoing dose escalation trial for ORIC-944 in combination with androgen receptor inhibitors in patients with mCRPC Entered into clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC-114 in combination with subcutaneous amivantamab for the first-line treatment of NSCLC patients with EGFR exon 20 insertion mutations Expects to report seven data readouts acro...
- David Nierengarten
- Dennis Pak
- Martin Fan
- Wedbush Research
UBI UBISOFT ENTERTAINMENT SA
SHAK SHAKE SHACK INC. CLASS A
WING WINGSTOP INC.
WEN WENDY'S COMPANY
WDC WESTERN DIGITAL CORPORATION
TXRH TEXAS ROADHOUSE INC.
TTWO TAKE-TWO INTERACTIVE SOFTWARE INC.
TSLA TESLA INC
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
RARE ULTRAGENYX PHARMACEUTICAL INC.
QLYS QUALYS INC.
PEGA PEGASYSTEMS INC.
PANW PALO ALTO NETWORKS INC.
NVDA NVIDIA CORPORATION
LOW LOWE'S COMPANIES INC.
IMAX IMAX CORPORATION
HD HOME DEPOT INC.
WELL WELLTOWER INC.
GOOGL ALPHABET INC. CLASS A
GERN GERON CORP.
FB FACEBOOK INC. CLASS A
EGP EASTGROUP PROPERTIES INC.
EBAY EBAY INC.
CYBR CYBERARK SOFTWARE LTD.
CRM SALESFORCE.COM INC.
CHKP CHECK POINT SOFTWARE TECHNOLOGIES LTD.
CAKE CHEESECAKE FACTORY INCORPORATED
BJRI BJ'S RESTAURANTS INC.
FND FLOOR & DECOR HOLDINGS INC. CLASS A
ROKU ROKU INC. CLASS A
VTR VENTAS INC.
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
GM GENERAL MOTORS COMPANY
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
BKNG BOOKING HOLDINGS INC.
RH RESTORATION HARDWARE INC.
CRWD CROWDSTRIKE HOLDINGS INC. CLASS A
PEAK HEALTHPEAK PROPERTIES INC.
IDYA IDEAYA BIOSCIENCES
ORIC ORIC PHARMACEUTICALS
FUBO FUBOTV
RZLT REZOLUTE
DASH DOORDASH
ABNB AIRBNB INC. CLASS A
RBLX ROBLOX
TTD THE TRADE DESK
TOST INC.
EWTX TOAST INC
EMBRAC B EDGEWISE THERAPEUTICS INC
EMBRACER GROUP AB
- David Nierengarten
- Dennis Pak
- Martin Fan
- Wedbush Research
- David Nierengarten
- Dennis Pak
- Martin Fan
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Ru...
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Feb. 07, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on February 3, 2025 (the “Grant Date”), ORIC granted a total of 29,600 non-qualified stock options and 4,800 restricted stock units to two new non-executive employees who began their employment with ORIC in January 2025. These inducement grants were g...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.